Filters

ADAM13 Antibody, FITC Conjugated

ADAM13 Antibody, FITC Conjugated size: 0.1ml 333

Price 333
Size 0.1ml
Long name FITC Conjugated, ADAM13 Polyclonal Antibody
CategoryConjugated Primary Antibodies
ConjugationAnti-FITC Antibody
Host OrganismRabbit (Oryctolagus cuniculus)
Target AntigenADAM13
SpecificityThis is a highly specific antibody against ADAM13
ModificationUnmodified
Modification siteNone
ClonalityPolyclonal
ClonePolyclonal antibody
Concentration1ug per 1ul
SourceKLH conjugated synthetic peptide derived from Xenopus laevis ADAM13
Tested applicationsIF(IHC-P)
Recommended dilutionsIF(IHC-P)(1:50-200)
CrossreactivityOther Species
Crossreactive species detailsXenopus laevis
Antigen background A member of the metalloproteinase family containing disintegrin like domains (ADAMs) the functions of ADAM13 are still poorly understood, ADAM13 contains a putative furin cleavage site, ADAM13 contains the canonical HExxHxxxxxH zinc metalloproteinase motif, ADAM13 has been shown to be proteolytically active, ADAM13 is also shed from cells in culture, ADAM13 may also act as a cell attachment molecule, ADAM13 may regulate cellular signaling via Src and Src tyrosine kinase, ADAM13 was also found in liver, EFG like, It is still unclear if any of these ADAMs are species orthologs of Xenopus ADAM13, Predicted mass is 99, Shed ADAM13 is a 52 kD protein, The full length Xenopus ADAM13 sequence codes for a 914 amino acid protein, Xenopus ADAM13 has greatest homology with human ADAM 33 (51% identical), and 97 kD processed forms, and can form complexes with a2 macroglobulin, and intestines from adult Xenopus, and is 46% identical with human or mouse ADAM12 or ADAM19, and is released into the culture media, as well as disintegrin, but glycosylation and cyteine rich regions give Xenopus ADAM13 an apparent MW of 120 kD unprocessed, but there are significant differences between the related sequences, by binding integrins through the cysteine rich domain amoung many other roles, cleaved aminoterminal from the transmembrane domain, cleaving fibronectin after binding it to the EGF like domain, cysteine rich, heart, in developing Xenopus embryos, on reduced SDS PAGE gels, suggesting it is a competent protease, suggesting that ADAM13 may be a unique protein, suggesting that a prohormone convertase cleaves the propeptide domain away from the catalytic domain, transmembrane and Cytoplasmic domains, 749 kD, ADAM13 was first described as a protein expressed in somatic mesoderm and neural crest cells
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA
Excitation Emission494nm/518nm
SynonymsNULL
Properties Bioss Primary Conjugated Antibodies FITC is highly sensitive to pH extremes, FITC has a green emission that's usually collected at 530 nanometers, FITC has a high quantum yield (efficiency of energy transfer from absorption to emission fluorescence) and approximately half of the absorbed photons are emitted as fluorescent light, For fluorescent microscopy applications, This Bioss Primary Conjugated Antibodies Fluorescein isothiocyanate (FITC) antibody is currently after some BD antibodies the most commonly used fluorescent dye for FACS, When excited at 488 nanometers, its photo bleaching effects are not observed due to a very brief interaction at the laser intercept, the 1 FITC is seldom used as it photo bleaches rather quickly though in flow cytometry applications, the FL1 detector of a FACSCalibur or FACScan, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°
Gene targetADAM13 Conjugated
Short name FITC Conjugated, ADAM13 Antibody
Technique Fluorescein, antibodies against human proteins, antibodies for, antibody Conjugates, Antibody
LabelFITC
Alternative name fluorecein coupled, ADAM13 (Antibody to)
Alternative techniqueantibodies

Subscribe to our Newsletter